The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market’s growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.
The R&D spending was driven by increased clinical manufacturing activities, with the company’s Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.
The R&D spending was driven by increased clinical manufacturing activities, with the company’s Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.
mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights
- The viral vaccines segment dominated the market with a share of 100.00% in 2023. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
- The infectious diseases segment held the largest market share in 2023 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
- The biotech companies end-use segment dominated the market and accounted for a share of more than 60.00% in 2023. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
- Asia Pacific is expected to register the fastest growth rate of 10.83% from 2024 to 2030. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: CAGR Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
2.2 Segment Snapshot
2.3 Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
3.2.1.3 Major Funding For Mrna Research
3.2.2 Market Restraint Analysis
3.2.2.1 Availability of Low-cost Substitute Therapies
3.2.2.2 High Research Cost
3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
3.4 COVID-19 Impact Analysis
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.1.2.1 Global Recombinant Protein Therapeutics CDMO Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rapid Adoption Of Mrna In Vaccine Development
3.2.1.2 Multiple Research Efforts On Mrna Therapeutics
3.2.1.3 Major Funding For Mrna Research
3.2.2 Market Restraint Analysis
3.2.2.1 Availability of Low-cost Substitute Therapies
3.2.2.2 High Research Cost
3.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
3.4 COVID-19 Impact Analysis
Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis
4.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Application Segment: Key Takeaways
4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
4.4 Viral Vaccines
4.4.1 Viral Vaccines Market, 2018-2030 (USD Million)
4.5 Protein Replacement Therapies
4.5.1 Protein Replacement Therapies Market, 2018-2030 (USD Million)
4.6 Cancer Immunotherapies
4.6.1 Cancer Immunotherapies Market, 2018-2030 (USD Million)
4.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Movement Analysis
4.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Application (USD Million)
4.4 Viral Vaccines
4.4.1 Viral Vaccines Market, 2018-2030 (USD Million)
4.5 Protein Replacement Therapies
4.5.1 Protein Replacement Therapies Market, 2018-2030 (USD Million)
4.6 Cancer Immunotherapies
4.6.1 Cancer Immunotherapies Market, 2018-2030 (USD Million)
Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis
5.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Indication Segment: Key Takeaways
5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
5.4 Infectious Diseases
5.4.1 Infectious Diseases Market, 2018-2030 (USD Million)
5.5 Metabolic & Genetic Diseases
5.5.1 Metabolic & Genetic Diseases Market, 2018-2030 (USD Million)
5.6 Cardiovascular & Cerebrovascular Diseases
5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2018-2030 (USD Million)
5.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Movement Analysis
5.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by Indication (USD Million)
5.4 Infectious Diseases
5.4.1 Infectious Diseases Market, 2018-2030 (USD Million)
5.5 Metabolic & Genetic Diseases
5.5.1 Metabolic & Genetic Diseases Market, 2018-2030 (USD Million)
5.6 Cardiovascular & Cerebrovascular Diseases
5.6.1 Cardiovascular & Cerebrovascular Diseases Market, 2018-2030 (USD Million)
Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis
6.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by End-use Segment: Key Takeaways
6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
6.4 Biotech Companies
6.4.1 Biotech Companies Market, 2018-2030 (USD Million)
6.5 Pharmaceutical Companies
6.5.1 Pharmaceutical Companies Market, 2018-2030 (USD Million)
6.6 Government & Academic Research Institutes
6.6.1 Government & Academic Research Institutes Market, 2018-2030 (USD Million)
6.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Movement Analysis
6.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates & Forecast by End-use (USD Million)
6.4 Biotech Companies
6.4.1 Biotech Companies Market, 2018-2030 (USD Million)
6.5 Pharmaceutical Companies
6.5.1 Pharmaceutical Companies Market, 2018-2030 (USD Million)
6.6 Government & Academic Research Institutes
6.6.1 Government & Academic Research Institutes Market, 2018-2030 (USD Million)
Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis
7.1 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market by Regional Segment: Key Takeaways
7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
7.4 North America
7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.4.2 U.S.
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.4.3 Canada
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5 Europe
7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.2 UK
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.3 Germany
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.4 France
7.5.4.1 Key Country Dynamics
7.5.4.2 Competitive Scenario
7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.5 Italy
7.5.5.1 Key Country Dynamics
7.5.5.2 Competitive Scenario
7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.6 Spain
7.5.6.1 Key Country Dynamics
7.5.6.2 Competitive Scenario
7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.7 Denmark
7.5.7.1 Key Country Dynamics
7.5.7.2 Competitive Scenario
7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.8 Sweden
7.5.8.1 Competitive Scenario
7.5.8.2 Key Country Dynamics
7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.9 Norway
7.5.9.1 Key Country Dynamics
7.5.9.2 Competitive Scenario
7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (Usd Million
7.6.2 Japan
7.6.2.1 Key Country Dynamics
7.6.2.2 Competitive Scenario
7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.3 China
7.6.3.1 Key Country Dynamics
7.6.3.2 Competitive Scenario
7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.4 India
7.6.4.1 Key Country Dynamics
7.6.4.2 Competitive Scenario
7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.5 Australia
7.6.5.1 Key Country Dynamics
7.6.5.2 Competitive Scenario
7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.6 South Korea
7.6.6.1 Key Country Dynamics
7.6.6.2 Competitive Scenario
7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.7 Indonesia
7.6.7.1 Key Country Dynamics
7.6.7.2 Competitive Scenario
7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7 Latin America
7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.2 Brazil
7.7.2.1 Key Country Dynamics
7.7.2.2 Competitive Scenario
7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.3 Mexico
7.7.3.1 Key Country Dynamics
7.7.3.2 Competitive Scenario
7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.4 Argentina
7.7.4.1 Key Country Dynamics
7.7.4.2 Competitive Scenario
7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8 MEA
7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.2 South Africa
7.8.2.1 Key Country Dynamics
7.8.2.2 Competitive Scenario
7.8.3 Saudi Arabia
7.8.3.1 Key Country Dynamics
7.8.3.2 Competitive Scenario
7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.4 UAE
7.8.4.1 Key Country Dynamics
7.8.4.2 Competitive Scenario
7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.5 Kuwait
7.8.5.1 Key Country Dynamics
7.8.5.2 Competitive Scenario
7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.2 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Share Analysis, 2023 & 2030
7.3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO): Market Estimates and Forecast, by Region (USD Million)
7.4 North America
7.4.1 North America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.4.2 U.S.
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.4.3 Canada
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5 Europe
7.5.1 Europe Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.2 UK
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.3 Germany
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.4 France
7.5.4.1 Key Country Dynamics
7.5.4.2 Competitive Scenario
7.5.4.3 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.5 Italy
7.5.5.1 Key Country Dynamics
7.5.5.2 Competitive Scenario
7.5.5.3 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.6 Spain
7.5.6.1 Key Country Dynamics
7.5.6.2 Competitive Scenario
7.5.6.3 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.7 Denmark
7.5.7.1 Key Country Dynamics
7.5.7.2 Competitive Scenario
7.5.7.3 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.8 Sweden
7.5.8.1 Competitive Scenario
7.5.8.2 Key Country Dynamics
7.5.8.3 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.5.9 Norway
7.5.9.1 Key Country Dynamics
7.5.9.2 Competitive Scenario
7.5.9.3 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6 Asia Pacific
7.6.1 Asia Pacific Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (Usd Million
7.6.2 Japan
7.6.2.1 Key Country Dynamics
7.6.2.2 Competitive Scenario
7.6.2.3 Japan Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.3 China
7.6.3.1 Key Country Dynamics
7.6.3.2 Competitive Scenario
7.6.3.3 China Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.4 India
7.6.4.1 Key Country Dynamics
7.6.4.2 Competitive Scenario
7.6.4.3 India Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.5 Australia
7.6.5.1 Key Country Dynamics
7.6.5.2 Competitive Scenario
7.6.5.3 Australia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.6 South Korea
7.6.6.1 Key Country Dynamics
7.6.6.2 Competitive Scenario
7.6.6.3 South Korea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.6.7 Indonesia
7.6.7.1 Key Country Dynamics
7.6.7.2 Competitive Scenario
7.6.7.3 Indonesia Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7 Latin America
7.7.1 Latin America Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.2 Brazil
7.7.2.1 Key Country Dynamics
7.7.2.2 Competitive Scenario
7.7.2.3 Brazil Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.3 Mexico
7.7.3.1 Key Country Dynamics
7.7.3.2 Competitive Scenario
7.7.3.3 Mexico Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.7.4 Argentina
7.7.4.1 Key Country Dynamics
7.7.4.2 Competitive Scenario
7.7.4.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8 MEA
7.8.1 Mea Mrna Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.2 South Africa
7.8.2.1 Key Country Dynamics
7.8.2.2 Competitive Scenario
7.8.3 Saudi Arabia
7.8.3.1 Key Country Dynamics
7.8.3.2 Competitive Scenario
7.8.3.3 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.4 UAE
7.8.4.1 Key Country Dynamics
7.8.4.2 Competitive Scenario
7.8.4.3 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
7.8.5 Kuwait
7.8.5.1 Key Country Dynamics
7.8.5.2 Competitive Scenario
7.8.5.3 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market Estimates And Forecasts, 2021-2030 (USD Million)
Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape
8.1. Market Participant Categorization
8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Service Launches
8.3.3. Acquisition
8.3.4. Partnerships/Agreements/Collaboration
8.3.5. Expansions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Danaher (Aldevron)
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Biomay AG
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Bio-Synthesis, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. eTheRNA
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Kaneka Eurogentec S.A.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. TriLink BioTechnologies
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. ApexBio Technology
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. BioNTech SE
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BioCina
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Lonza
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Recipharm AB
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Novo Holdings (Catalent, Inc.)
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
8.4.14. Samsung Biologics
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product/service benchmarking
8.4.14.4. Strategic initiatives
8.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Service Launches
8.3.3. Acquisition
8.3.4. Partnerships/Agreements/Collaboration
8.3.5. Expansions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Danaher (Aldevron)
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Biomay AG
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Bio-Synthesis, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. eTheRNA
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Kaneka Eurogentec S.A.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. TriLink BioTechnologies
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. ApexBio Technology
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. BioNTech SE
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. BioCina
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Lonza
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Recipharm AB
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Novo Holdings (Catalent, Inc.)
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
8.4.14. Samsung Biologics
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product/service benchmarking
8.4.14.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 3 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 4 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 5 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 6 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 7 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 8 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 9 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 10 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 11 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 12 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 13 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 14 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 15 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 16 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 17 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 18 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 19 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 20 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 21 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 22 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 23 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 24 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 25 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 26 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 27 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 28 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 29 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 30 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 31 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 32 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 33 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 34 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 35 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 36 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 37 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 38 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 39 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 40 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 41 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 42 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 43 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 44 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 45 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 46 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 47 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 48 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 49 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 50 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 51 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 52 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 53 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 54 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 55 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 56 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 57 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 58 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 59 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 60 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 61 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 62 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 63 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 64 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 65 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 66 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 67 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 68 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 69 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 70 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 71 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 72 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 73 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 74 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 75 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 76 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 78 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 80 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 81 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 82 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 83 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 84 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 85 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 86 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 87 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 88 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 89 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 90 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 2 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 3 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 4 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 5 North America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 6 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 7 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 8 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 9 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 10 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 11 Canada mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 12 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 13 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 14 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 15 Europe mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 16 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 17 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 18 UK mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 19 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 20 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 21 Germany mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 22 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 23 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 24 France mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 25 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 26 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 27 Italy mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 28 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 29 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 30 Spain mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 31 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 32 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 33 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 34 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 35 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 36 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 37 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 38 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 39 Norway mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 40 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 41 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 42 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 43 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 44 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 45 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 46 Japan mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 47 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 48 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 49 China mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 50 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 51 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 52 India mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 53 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 54 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 55 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 56 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 57 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 58 Australia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 59 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 60 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 61 Indonesia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 62 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 63 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 64 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 65 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 66 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 67 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 68 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 69 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 70 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 71 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 72 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 73 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 74 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 75 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by region, 2018-2030 (USD Million)
Table 76 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 78 MEA mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 80 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 81 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 82 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 83 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 84 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 85 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 86 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 87 UAE mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
Table 88 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by application, 2018-2030 (USD Million)
Table 89 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by indication, 2018-2030 (USD Million)
Table 90 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 mRNA therapeutics contract development & manufacturing organization (CDMO) market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Data analysis models
Figure 5 Market formulation and validation
Figure 6 Data validating & publishing
Figure 7 Commodity flow analysis
Figure 8 Market snapshot
Figure 9 Segment snapshot
Figure 10 Segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Parent market outlook, 2023 (USD Billion)
Figure 13 Ancillary market outlook, 2023 (USD Billion)
Figure 14 mRNA therapeutics contract development & manufacturing organization (CDMO) market dynamics
Figure 15 Porter’s five forces analysis
Figure 16 PESTEL analysis
Figure 17 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application outlook and key takeaways
Figure 18 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application movement analysis
Figure 19 Viral vaccines market estimates and forecast, 2021-2030 (USD Million)
Figure 20 Protein replacement therapies market estimates and forecast, 2021-2030 (USD Million)
Figure 21 Cancer immunotherapies market estimates and forecast, 2021-2030 (USD Million)
Figure 22 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication outlook and key takeaways
Figure 23 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication movement analysis
Figure 24 Infectious diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 25 Metabolic & genetic diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 26 Cardiovascular & cerebrovascular diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 27 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use outlook and key takeaways
Figure 28 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use movement analysis
Figure 29 Biotech companies market estimates and forecast, 2021-2030 (USD Million)
Figure 30 Pharmaceutical companies market estimates and forecast, 2021-2030 (USD Million)
Figure 31 Government & academic research institutes market estimates and forecast, 2021-2030 (USD Million)
Figure 32 Regional market: Key takeaways
Figure 33 Regional outlook, 2023 & 2030
Figure 34 Regional outlook, 2023 & 2030
Figure 35 North America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 36 Key country dynamics
Figure 37 U.S. mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 38 Key country dynamics
Figure 39 Canada mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 40 Europe mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 41 Key country dynamics
Figure 42 UK mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 43 Key country dynamics
Figure 44 Germany mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 45 Key country dynamics
Figure 46 France mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 47 Key country dynamics
Figure 48 Italy mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 49 Key country dynamics
Figure 50 Spain mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Denmark mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 53 Key country dynamics
Figure 54 Sweden mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Norway mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 57 Asia Pacific mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Japan mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 60 Key country dynamics
Figure 61 China mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 62 Key country dynamics
Figure 63 India mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Australia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 66 Key country dynamics
Figure 67 South Korea mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 68 Key country dynamics
Figure 69 Indonesia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 70 Latin America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 71 Key country dynamics
Figure 72 Brazil mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 Mexico mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 75 Key country dynamics
Figure 76 Argentina mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 77 MEA mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 78 Key country dynamics
Figure 79 South Africa mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 80 Key country dynamics
Figure 81 Saudi Arabia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 82 Key country dynamics
Figure 83 UAE mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Kuwait mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 86 Market participant categorization
Figure 87 Heat map analysis
Figure 88 Strategy mapping
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Data analysis models
Figure 5 Market formulation and validation
Figure 6 Data validating & publishing
Figure 7 Commodity flow analysis
Figure 8 Market snapshot
Figure 9 Segment snapshot
Figure 10 Segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Parent market outlook, 2023 (USD Billion)
Figure 13 Ancillary market outlook, 2023 (USD Billion)
Figure 14 mRNA therapeutics contract development & manufacturing organization (CDMO) market dynamics
Figure 15 Porter’s five forces analysis
Figure 16 PESTEL analysis
Figure 17 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application outlook and key takeaways
Figure 18 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Application movement analysis
Figure 19 Viral vaccines market estimates and forecast, 2021-2030 (USD Million)
Figure 20 Protein replacement therapies market estimates and forecast, 2021-2030 (USD Million)
Figure 21 Cancer immunotherapies market estimates and forecast, 2021-2030 (USD Million)
Figure 22 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication outlook and key takeaways
Figure 23 mRNA therapeutics contract development & manufacturing organization (CDMO) market: Indication movement analysis
Figure 24 Infectious diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 25 Metabolic & genetic diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 26 Cardiovascular & cerebrovascular diseases market estimates and forecast, 2021-2030 (USD Million)
Figure 27 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use outlook and key takeaways
Figure 28 mRNA therapeutics contract development & manufacturing organization (CDMO) market: End use movement analysis
Figure 29 Biotech companies market estimates and forecast, 2021-2030 (USD Million)
Figure 30 Pharmaceutical companies market estimates and forecast, 2021-2030 (USD Million)
Figure 31 Government & academic research institutes market estimates and forecast, 2021-2030 (USD Million)
Figure 32 Regional market: Key takeaways
Figure 33 Regional outlook, 2023 & 2030
Figure 34 Regional outlook, 2023 & 2030
Figure 35 North America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 36 Key country dynamics
Figure 37 U.S. mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 38 Key country dynamics
Figure 39 Canada mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 40 Europe mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 41 Key country dynamics
Figure 42 UK mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 43 Key country dynamics
Figure 44 Germany mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 45 Key country dynamics
Figure 46 France mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 47 Key country dynamics
Figure 48 Italy mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 49 Key country dynamics
Figure 50 Spain mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Denmark mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 53 Key country dynamics
Figure 54 Sweden mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Norway mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 57 Asia Pacific mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Japan mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 60 Key country dynamics
Figure 61 China mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 62 Key country dynamics
Figure 63 India mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Australia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 66 Key country dynamics
Figure 67 South Korea mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 68 Key country dynamics
Figure 69 Indonesia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 70 Latin America mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 71 Key country dynamics
Figure 72 Brazil mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 Mexico mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 75 Key country dynamics
Figure 76 Argentina mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 77 MEA mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 78 Key country dynamics
Figure 79 South Africa mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 80 Key country dynamics
Figure 81 Saudi Arabia mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 82 Key country dynamics
Figure 83 UAE mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Kuwait mRNA therapeutics contract development & manufacturing organization (CDMO) market estimates and forecasts, 2021-2030 (USD Million)
Figure 86 Market participant categorization
Figure 87 Heat map analysis
Figure 88 Strategy mapping
Companies Mentioned
- Danaher (Aldevron)
- Biomay AG
- Bio-Synthesis, Inc.
- eTheRNA
- Kaneka Eurogentec S.A.
- TriLink BioTechnologies
- ApexBio Technology
- BioNTech SE
- BioCina
- Lonza
- Recipharm AB
- Novo Holdings (Catalent, Inc.)
- Samsung Biologics
Methodology
LOADING...
